Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May...
Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis PR...
Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at...
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update Canada NewsWire VICTORIA, BC, May 8, 2024...
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board PR Newswire VICTORIA, BC, May 2, 2024 --Advisory Board to Provide...
Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024 PR...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.